Retrospective Study
Copyright ©The Author(s) 2023.
World J Clin Cases. Apr 6, 2023; 11(10): 2226-2236
Published online Apr 6, 2023. doi: 10.12998/wjcc.v11.i10.2226
Table 4 Intestinal microbiota indications in coronavirus disease 19 patients compared with the control group Me (UQ; LQ)
Symptom
Patients with COVID-19 (n = 80)
Control group (n = 17)
P value
Eubacterium/Cl. Coccoides, amt. × 1056849 (3380-7987)8211 (2996-10987)0.17
Herpes, amt. × 1050.00 (0.00-1808.25)3610 (1914-5316)0.001
Propionibacterium/Cl. Subterminale, amt. × 1052706 (1614-3476)1992 (704-2118)0.0016
Bifidobacteria, amt. × 1053768 (2000-4678)4614 (1653-6123)0.13
Fungus, amt. × 1051200 (423-1851)540 (384-774)0.0406
Lactobacillus, amt. × 1057488 (4221-8790)4309 (2521-5198)0.0016
The ratio of anaerobic to aerobic flora1.801 (0.718-3.01)1.983 (0.637-3.09)0.39
The ratio of beneficial flora to opportunistic1.009 (0.359-2.110)0.992 (0.300-1.990)0.86
Beneficial flora, amt. × 10520953 (5508-36018)19126 (3930-35764)0.18
Sum, amt. × 10544651 (8152-97098)42566 (6297-89016)0.33
Large intestine (anaerobes), amt. × 10526171 (7088-44099)24964 (4423-43871)0.44
Small intestine (aerobes), amt. × 10515944 (4620-19087)13570 (3692-20114)0.06
Opportunistic flora, amt. × 10521927 (5493-25900)19849 (3690-23983)0.11
Cytomegalovirus, amt. × 1050.00 (0.00-40.00)0.00 (0.00-0.00)0.12
Endotoxin (sum), amt. × 1052.44 (1.21-6.11)0.689 (0.490-1.11)0.0000779